Clinical trial
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and…
NCT04613596 · Mirati Therapeutics Inc., Industry · Recruiting
Key facts
| NCT number | NCT04613596 |
|---|---|
| Title | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 |
| Official title | A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation |
| Lead sponsor | Mirati Therapeutics Inc., Industry |
| Status | Recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Adagrasib, Pembrolizumab |
| Enrollment | 806 |
| Start date | Dec 2, 2020 |
| Primary completion | Oct 31, 2028 |
| Completion | Oct 31, 2029 |
| First posted | Nov 3, 2020 |
| Last update posted | Feb 13, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia and 35 more |
At a glance
- 1,000+ Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: